v3.26.1
Commitments and Contingencies - Legal Proceedings (Details)
$ in Millions
3 Months Ended 6 Months Ended
Mar. 31, 2026
USD ($)
Jun. 30, 2026
USD ($)
lawsuit
Dec. 31, 2025
USD ($)
Loss Contingencies [Line Items]      
Finite-lived intangible assets, net   $ 109 $ 45
Arbutus Biopharma Corporation (Arbutus) and Genevant Sciences GmbH (Genevant)      
Loss Contingencies [Line Items]      
Litigation settlement liability   950  
Amount awarded to other party $ 876    
Loss contingency, estimate of possible loss $ 74    
Arbutus Biopharma Corporation (Arbutus) and Genevant Sciences GmbH (Genevant) | Maximum      
Loss Contingencies [Line Items]      
Litigation liability   1,300  
Arbutus Biopharma Corporation (Arbutus) and Genevant Sciences GmbH (Genevant) | Intellectual Property      
Loss Contingencies [Line Items]      
Finite-lived intangible asset, useful life 3 years    
Finite-lived intangible assets, net   $ 66  
GlaxoSmithKline Biologicals      
Loss Contingencies [Line Items]      
Number of patent infringement cases | lawsuit   2